Amylyx Pharmaceuticals, Inc.
AMLXNasdaqCIK 1658551HealthcareFiscal year ends Dec 31
Reports and events: 87 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-0820:54 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-26-385331 |
| 2026-08-2021:28 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-359418 |
| 2026-08-1813:03 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-354793 |
| 2026-08-1811:09 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-354716 |
| 2026-08-0611:04 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-336682 |
| 2026-08-0611:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336670 |
| 2026-06-0420:06 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-257390 |
| 2026-05-0711:04 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-210292 |
| 2026-05-0711:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210286 |
| 2026-04-2311:01 ET | DEF 14A | Proxy statementPeriod 2026-06-04 | 0001193125-26-171800 |
| 2026-03-2411:11 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-120691 |
| 2026-03-0312:10 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-086645 |
| 2026-03-0312:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-086629 |
| 2026-01-0812:03 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-006991 |
| 2025-11-0612:11 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-268059 |
| 2025-11-0612:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-268043 |
| 2025-09-1020:55 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-200159 |
| 2025-08-2711:05 ET | 8-K | 8.01 Other events | 0001193125-25-189109 |
| 2025-08-0711:15 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001193125-25-174948 |
| 2025-08-0711:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-104546 |
| 2025-06-0520:04 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-135860 |
| 2025-05-0811:04 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-066363 |
| 2025-05-0811:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-066355 |
| 2025-04-2411:05 ET | DEF 14A | Proxy statementPeriod 2025-06-05 | 0000950170-25-057665 |
| 2025-03-0411:24 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-031309 |
| 2025-03-0411:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-031303 |
| 2025-01-1022:23 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-004547 |
| 2024-12-3012:50 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-24-286212 |
| 2024-11-0713:22 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-122833 |
| 2024-11-0712:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122779 |
| 2024-10-1713:12 ET | 8-K | 8.01 Other events | 0001193125-24-238572 |
| 2024-08-0811:14 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-093311 |
| 2024-08-0811:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093304 |
| 2024-07-1011:09 ET | 8-K | 2.01 Completion of an acquisition or disposition | 0001193125-24-177000 |
| 2024-06-2121:07 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-24-076339 |
| 2024-06-0620:07 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-156050 |
| 2024-05-0911:12 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-056269 |
| 2024-05-0911:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-056254 |
| 2024-04-2411:07 ET | DEF 14A | Proxy statementPeriod 2024-06-06 | 0000950170-24-047243 |
| 2024-04-1013:19 ET | 8-K | 8.01 Other events | 0001193125-24-091463 |
| 2024-04-0411:10 ET | 8-K | 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-086609 |
| 2024-03-1413:18 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-067471 |
| 2024-03-0812:10 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-062878 |
| 2024-02-2213:22 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-018447 |
| 2024-02-2212:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-018409 |
| 2023-12-0712:00 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-23-290302 |
| 2023-11-0912:07 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-061516 |
| 2023-11-0911:58 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-061505 |
| 2023-10-1321:20 ET | 8-K | 8.01 Other events | 0001193125-23-256178 |
| 2023-10-0420:19 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-23-250741 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.